open access
The use of cilostazol in intermittent claudication in patients with peripheral arterial disease
open access
Abstract
Intermittent claudication is the most frequent one symptom of peripheral arterial disease (PAD). Extending the distance free from pain is achieved by surgical treatment, endovascular and appropriate pharmacotherapy. Phosphodiesterase III (PDE) are a group of drugs that have a very strong anti-aggregation effect. In addition, they have vasodilator activity, lipid-lowering and anti-proliferative what makes them the subject of numerous scientific publications. Cilostazol is the best studied PDE inhibitor. Though not devoid of side effects the drug has been shown to influence the extension of claudication distance. Compared to the placebo and pentoxifylline significantly affect the maximum claudication distance (MWD) and pain-free distance (PWD). In addition, effectively prevents restenosis after endovascular treatment of coronary and peripheral vessels. Cilostazol may also be an alternative in the case of the development of resistance to conventional anti-platelet agents. TASC II guidelines recommend the use of 3–6 months treatment with cilostazol in alleviating the symptoms of intermittent claudication. Treatment for monitoring and verification requires specialist.
Abstract
Intermittent claudication is the most frequent one symptom of peripheral arterial disease (PAD). Extending the distance free from pain is achieved by surgical treatment, endovascular and appropriate pharmacotherapy. Phosphodiesterase III (PDE) are a group of drugs that have a very strong anti-aggregation effect. In addition, they have vasodilator activity, lipid-lowering and anti-proliferative what makes them the subject of numerous scientific publications. Cilostazol is the best studied PDE inhibitor. Though not devoid of side effects the drug has been shown to influence the extension of claudication distance. Compared to the placebo and pentoxifylline significantly affect the maximum claudication distance (MWD) and pain-free distance (PWD). In addition, effectively prevents restenosis after endovascular treatment of coronary and peripheral vessels. Cilostazol may also be an alternative in the case of the development of resistance to conventional anti-platelet agents. TASC II guidelines recommend the use of 3–6 months treatment with cilostazol in alleviating the symptoms of intermittent claudication. Treatment for monitoring and verification requires specialist.
Keywords
intermittent claudication, cilostazol, lower limb ischemia, peripheral arterial disease
About this articleTitle
The use of cilostazol in intermittent claudication in patients with peripheral arterial disease
Journal
Issue
Article type
Review paper
Pages
101-105
Published online
2014-12-10
Page views
1065
Article views/downloads
4590
DOI
10.5603/aa.40445
Bibliographic record
Acta Angiologica 2014;20(3):101-105.
Keywords
intermittent claudication
cilostazol
lower limb ischemia
peripheral arterial disease
Authors
Paweł Wierzchowski
Arkadiusz Migdalski
Arkadiusz Jawień